Tezepelumab Biosimilar(Mabpharm)

特泽利尤单抗生物类似药（迈博药业）

Report date: 2025/11/28 16:52:19

Base Information

Drug NameTezepelumab Biosimilar(Mabpharm)
Drug Alias NameCMAB023CMAB-023
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionThymic stromal lymphopoietin inhibitors
TargetsThymic stromal lymphopoietin
Therapy Area/IndicationsAsthma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesMabpharm Ltd
China Registration ClassN/A

Develop Information

Active CompaniesMabpharm Ltd
Inactive CompaniesN/A
Active IndicationsAsthma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A